Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a... see more

Recent & Breaking News (NDAQ:IKT)

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 20, 2025

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 20, 2025

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

GlobeNewswire November 20, 2025

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

GlobeNewswire November 14, 2025

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

GlobeNewswire August 19, 2025

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

GlobeNewswire August 14, 2025

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

GlobeNewswire May 14, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

PR Newswire May 5, 2025

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

GlobeNewswire April 14, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

GlobeNewswire March 27, 2025

Inhibikase Announces Expansion of Senior Leadership Team

GlobeNewswire February 24, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

GlobeNewswire February 18, 2025

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

GlobeNewswire November 14, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 21, 2024

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 9, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire August 14, 2024

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

GlobeNewswire August 7, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

GlobeNewswire June 17, 2024

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

GlobeNewswire June 5, 2024

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

GlobeNewswire May 20, 2024

Podcasts